APP-dependent alteration of GSK3β activity impairs neurogenesis in the Ts65Dn mouse model of Down syndrome
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Intellectual disability in Down syndrome (DS) appears to be related to severe neurogenesis impairment during brain development. The molecular mechanisms underlying this defect are still largely unknown. Accumulating evidence has highlighted the importance of GSK3β signaling for neuronal precursor proliferation/differentiation. In neural precursor cells (NPCs) from Ts65Dn mice and human fetuses with DS, we found reduced GSK3β phosphorylation and, hence, increased GSK3β activity. In cultures of trisomic subventricular-zone-derived adult NPCs (aNPCs) we found that deregulation of GSK3β activity was due to higher levels of the AICD fragment of the trisomic gene APP that directly bound to GSK3β. We restored GSK3β phosphorylation in trisomic aNPCs using either lithium, a well-known GSK3β inhibitor, or using a 5-HT receptor agonist or fluoxetine, which activated the serotonin receptor 5-HT1A. Importantly, this effect was accompanied by restoration of proliferation, cell fate specification and neuronal maturation. In agreement with results obtained in vitro, we found that early treatment with fluoxetine, which was previously shown to rescue neurogenesis and behavior in Ts65Dn mice, restored GSK3β phosphorylation. These results provide a link between GSK3β activity alteration, APP triplication and the defective neuronal production that characterizes the DS brain. Knowledge of the molecular mechanisms underlying neurogenesis alterations in DS may help to devise therapeutic strategies, potentially usable in humans. Results suggest that drugs that increase GSK3β phosphorylation, such as lithium or fluoxetine, may represent useful tools for the improvement of neurogenesis in DS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WNT and β-catenin signalling: diseases and therapies
Moon, R. T., Kohn, A. D., Ferrari, G. V. D., & Kaykas, A. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1427 · Cited by 1,763 · cited 1×
“Recent evidence shows that β-catenin, besides being involved in a variety of functions (Moon et al., 2004; Toledo et al., 2008), plays an important role in regulating proliferation of neural stem cells.”
BackgroundRegulation of Cerebral Cortical Size by Control of Cell Cycle Exit in Neural Precursors
Chenn, A., & Walsh, C. A. (2002) · Science · doi:10.1126/science.1074192 · Cited by 1,431 · cited 1×
“In these cells, βcatenin acts downstream from the canonical Wnt-signaling pathway (Chenn and Walsh, 2002; Chenn and Walsh, 2003) and appears to increase proliferation by decreasing cell cycle exit (Chenn and Walsh, 2002).”
BackgroundA mouse model for Down syndrome exhibits learning and behaviour deficits
Reeves, R. H., Irving, N. G., Moran, T. H., Wohn, A., Kitt, C., Sisodia, S. S., Schmidt, C., Bronson, R. T., & Davisson, M. T. (1995) · Nature Genetics · doi:10.1038/ng1095-177 · Cited by 913 · cited 1×
“Female Ts65Dn mice carrying a segmental trisomy of chromosome 16 (Reeves et al., 1995) were obtained from Jackson Laboratories (Bar Harbour, ME, USA) and maintained on the original genetic background by mating them to C57BL/6JEi × C3SnHeSnJ (B6EiC3) F1 males.”
MethodTakashima, S., Becker, L. E., Armstrong, D. L., & Chan, F. (1981) · Brain Research · doi:10.1016/0006-8993(81)90314-0 · Cited by 307
In Vivo Regulation of Glycogen Synthase Kinase-3β (GSK3β) by Serotonergic Activity in Mouse Brain
Li, X., Zhu, W., Roh, M.-S., Friedman, A. B., Rosborough, K., & Jope, R. S. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300439 · Cited by 300
Contestabile, A., Fila, T., Ceccarelli, C., Bonasoni, P., Bonapace, L., Santini, D., Bartesaghi, R., & Ciani, E. (2007) · Hippocampus · doi:10.1002/hipo.20308 · Cited by 281
Self-citationGuidi, S., Bonasoni, P., Ceccarelli, C., Santini, D., Gualtieri, F., Ciani, E., & Bartesaghi, R. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00113.x · Cited by 276 · cited 6×
“…with DS. Accumulating evidence in individualswith DS and DSmousemodels shows that brain hypotrophy is due to proliferation impairment (Chakrabarti et al., 2007; Contestabile et al., 2007; Guidi et al., 2008; Guidi et al., 2011; Haydar et al., 2000; Lorenzi and Reeves, 2006; Roper et al., 2006).”
BackgroundSelf-citationChenn, A. (2003) · Cerebral Cortex · doi:10.1093/cercor/13.6.599 · Cited by 253 · cited 1×
“In these cells, βcatenin acts downstream from the canonical Wnt-signaling pathway (Chenn and Walsh, 2002; Chenn and Walsh, 2003) and appears to increase proliferation by decreasing cell cycle exit (Chenn and Walsh, 2002).”
BackgroundBianchi, P., Ciani, E., Guidi, S., Trazzi, S., Felice, D., Grossi, G., Fernandez, M., Giuliani, A., Calza, L., & Bartesaghi, R. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.0534-10.2010 · Cited by 188 · cited 3×
“Consistently with current findings that lithium restores GSK3β activity and neurogenesis in trisomic aNPCs, treatmentwith lithium in adult Ts65Dn mice rescues neurogenesis, synaptic plasticity and memory (Bianchi et al., 2010a; Contestabile et al., 2013).”
BackgroundSelf-citationGSK‐3 in Neurodegenerative Diseases
Lei, P., Ayton, S., Bush, A. I., & Adlard, P. A. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/189246 · Cited by 177 · cited 2×
“Since a number of neurological disorders are associatedwith deficits in GSK3β signaling (Lei et al., 2011; Salcedo-Tello et al., 2011), we thought it was important to establish whether GSK3β activity is altered in DS at early phases of development.”
BackgroundGuidi, S., Ciani, E., Bonasoni, P., Santini, D., & Bartesaghi, R. (2011) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00459.x · Cited by 165 · cited 3×
“…with DS. Accumulating evidence in individualswith DS and DSmousemodels shows that brain hypotrophy is due to proliferation impairment (Chakrabarti et al., 2007; Contestabile et al., 2007; Guidi et al., 2008; Guidi et al., 2011; Haydar et al., 2000; Lorenzi and Reeves, 2006; Roper et al., 2006).”
BackgroundSelf-citationHippocampal hypocellularity in the Ts65Dn mouse originates early in development
Lorenzi, H. A., & Reeves, R. H. (2006) · Brain Research · doi:10.1016/j.brainres.2006.05.022 · Cited by 145
Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions
Sturgeon, X., & Gardiner, K. J. (2011) · Mammalian Genome · doi:10.1007/s00335-011-9321-y · Cited by 117
Lim, C. S., & Walikonis, R. S. (2008) · Cellular Signalling · doi:10.1016/j.cellsig.2007.12.013 · Cited by 80 · cited 1×
“Inhibition of GSK3β promotes dendritic growth in sympathetic, cortical and hippocampal neurons (Lim and Walikonis, 2008; Naska et al., 2006).”
Background
Cited by
Neurogenesis impairment: An early developmental defect in Down syndrome
Stagni, F., Giacomini, A., Emili, M., Guidi, S., & Bartesaghi, R. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.07.026 · Cited by 120
Self-citationCognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome
D. Hamlett, E., A. Boger, H., Ledreux, A., M. Kelley, C., J. Mufson, E., F. Falangola, M., N. Guilfoyle, D., A. Nixon, R., Patterson, D., Duval, N., et al. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150921095505 · Cited by 46
Aberrant Oligodendrogenesis in Down Syndrome: Shift in Gliogenesis?
Reiche, L., Küry, P., & Göttle, P. (2019) · Cells · doi:10.3390/cells8121591 · Cited by 28
Metadata
- Authors
- Trazzi, S., Fuchs, C., De Franceschi, M., Mitrugno, V. M., Bartesaghi, R., & Ciani, E.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 67
- Pages
- 24-36
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2075945023
- Cited by
- 38
- References
- 14
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.